Key result
Several new drugs and indications, including brensocatib, elinzanetant, zoliflodacin, finerenone, and cyclobenzaprine, were approved by the US FDA in late 2025 for primary care use.
Why the study?
In the second half of 2025, the US Food and Drug Administration approved several new drugs and new indications for existing therapies relevant to primary care practice.
This review highlights several new FDA-approved medications and indications relevant to primary care practice in late 2025.
Alerts primary care clinicians to newly approved therapies; leaves open questions on real-world effectiveness and guideline integration.
In the second half of 2025, the US Food and Drug Administration approved several new drugs that have relevance for those practicing in primary care. This article highlights the following new medications: brensocatib (Brinsupri), elinzanetant (Lynkuet), and zoliflodacin (Nuzolvence). Additionally, this article reviews newly approved indications for existing therapies, including finerenone (Kerendia) for heart failure with a left ventricular ejection fraction of >_ 40% and cyclobenzaprine hydrochloride sublingual tablets (Tonmya) for fibromyalgia.
No takes yet. Share an insight, caveat, or question.
Treadway et al. (2026) conducted a review in Various (including heart failure and fibromyalgia). Newly approved drugs (brensocatib, elinzanetant, zoliflodacin, finerenone, cyclobenzaprine) was evaluated. Several new drugs and indications, including brensocatib, elinzanetant, zoliflodacin, finerenone, and cyclobenzaprine, were approved by the US FDA in late 2025 for primary care use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: